News

Public · Published

RBC Capital maintains Alnylam Pharmaceuticals at Outperform, lowers price target to $280 from $345

RBC Capital kept its Outperform rating on Alnylam Pharmaceuticals but cut its price target to $280 from $345, an 18.8% decrease. The new target implies 60.9% upside from the October 29 close of $174.

Published:

Updated:

What happened

RBC Capital kept its Outperform rating on Alnylam Pharmaceuticals but cut its price target to $280 from $345, an 18.8% decrease. The new target implies 60.9% upside from the October 29 close of $174.

Confirmed

Global impact / market context

The lower target still sits far above the recent share price, so RBC sees large potential gains even after trimming its view. For investors, the gap suggests RBC expects Alnylam's drug pipeline or sales to recover, but with less confidence than before.

Analyst inference

Other recent analyst targets on Alnylam range from $243 to $354, so RBC's $280 sits in the middle of that spread. The range shows analysts disagree about the company's outlook, and RBC's cut moves it closer to the cautious end.

Analyst inference

What to watch

  1. RBC's $280 target implies 60.9% upside from the October 29 close of $174, a gap investors can compare with later share price moves. Confirmed
  2. Watch whether other analysts follow RBC and lower their targets, since the five most recent targets currently span $243 to $354. Proposed
  3. Track Alnylam's upcoming financial reports and drug news, because weaker results or delays could push targets lower, while positive updates could support the current range. Analyst inference

Evidence

  • Original source link unavailable